- Home
- AIRS vs ELDN Comparison
AIRS vs ELDN Comparison
Compare AIRS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- ELDN
- Stock Information
- Founded
- AIRS 2012
- ELDN 2004
- Country
- AIRS United States
- ELDN United States
- Employees
- AIRS N/A
- ELDN N/A
- Industry
- AIRS Medical/Nursing Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- ELDN Health Care
- Exchange
- AIRS Nasdaq
- ELDN Nasdaq
- Market Cap
- AIRS 166.3M
- ELDN 178.4M
- IPO Year
- AIRS 2021
- ELDN N/A
- Fundamental
- Price
- AIRS $4.90
- ELDN $2.74
- Analyst Decision
- AIRS Hold
- ELDN Strong Buy
- Analyst Count
- AIRS 3
- ELDN 2
- Target Price
- AIRS $3.75
- ELDN $12.50
- AVG Volume (30 Days)
- AIRS 698.1K
- ELDN 224.2K
- Earning Date
- AIRS 08-08-2025
- ELDN 08-18-2025
- Dividend Yield
- AIRS N/A
- ELDN N/A
- EPS Growth
- AIRS N/A
- ELDN N/A
- EPS
- AIRS N/A
- ELDN N/A
- Revenue
- AIRS $172,101,000.00
- ELDN N/A
- Revenue This Year
- AIRS N/A
- ELDN N/A
- Revenue Next Year
- AIRS $4.90
- ELDN N/A
- P/E Ratio
- AIRS N/A
- ELDN N/A
- Revenue Growth
- AIRS N/A
- ELDN N/A
- 52 Week Low
- AIRS $1.53
- ELDN $2.30
- 52 Week High
- AIRS $9.20
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- AIRS 58.37
- ELDN 40.39
- Support Level
- AIRS $4.62
- ELDN $2.60
- Resistance Level
- AIRS $5.28
- ELDN $2.90
- Average True Range (ATR)
- AIRS 0.48
- ELDN 0.16
- MACD
- AIRS -0.07
- ELDN -0.02
- Stochastic Oscillator
- AIRS 57.25
- ELDN 24.35
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.